Simcere Pharmaceutical Group Limited (“Simcere”) announced that, effective 20 August 2026, Mr. Wan Yushan has stepped down as joint company secretary. He continues to serve as executive director and chief financial officer and confirmed no disagreement with the board or outstanding matters requiring shareholder attention.

Concurrently, Mr. Zhu Da, currently Simcere’s board secretary, has been appointed joint company secretary. He will work alongside Ms. Mak Po Man Cherie, who remains in her role and meets the professional qualifications stipulated in Rule 3.28 of the Hong Kong Listing Rules.

Although Mr. Zhu lacks the full professional credentials required under Rules 3.28 and 8.17, the Hong Kong Stock Exchange has granted Simcere a waiver from strict compliance for three years (20 August 2026 – 19 August 2029). Key conditions are: 1. Mr. Zhu must be assisted by Ms. Mak throughout the waiver period. 2. The waiver may be revoked upon any material breach of the Listing Rules.

Before the waiver expires, Simcere must demonstrate that Mr. Zhu has acquired sufficient experience to fulfil the company secretary role independently, otherwise a further waiver will be required.

As at the announcement date, Simcere’s board comprises one chairman and executive director (Mr. Ren Jinsheng), two additional executive directors (Mr. Wan Yushan, Ms. Wang Xi), one non-executive director (Mr. Tang Renhong) and four independent non-executive directors (Mr. Song Ruilin, Mr. Wang Jianguo, Mr. Wang Xinhua, Mr. Sung Ka Woon).